Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12901417 | 0.86 | CES2 (0.34) | — | |
| SCHEMBL21077943 | 0.83 | — | — | |
| SCHEMBL14465255 | 0.81 | — | — | |
| SCHEMBL8552453 | 0.77 | — | — | |
| SCHEMBL31373041 | 0.76 | CA1 (0.30) | — | |
| SCHEMBL11289792 | 0.76 | — | — | |
| SCHEMBL26085414 | 0.75 | CES2 (0.33) | — | |
| SCHEMBL20910349 | 0.75 | CES2 (0.33) | — | |
| SCHEMBL620412 | 0.74 | CA1 (0.36) | — | |
| SCHEMBL6995147 | 0.74 | HTT (0.32) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931082-B1 | NODULISPORIC ACID DERIVATIVES | MERCK & CO INC (US) | 2003-03-19 | — | — | EP | claimed |
| US-6221894-B1 | ACARICIDAL, ANTIPARASITIC, INSECTICIDAL AND ANTHELMINTIC AGENTS. | MERCK & CO., INC. | 2001-04-24 | — | — | US | claimed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20140057893-A1 | SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8318705-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012138845-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2009137717-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | EVOTEC LTD. (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | EVOTEC LTD. (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-0931082-B1 | NODULISPORIC ACID DERIVATIVES | MERCK & CO INC (US) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057893-A1 | SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | HTT 2788/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | HTT 2323/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | HTT 2323/4885 |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | HTT 4231/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | HTT 2323/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | HTT 3689/4885 |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | HTT 2710/4885 |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | NOXO1, TNNI3, HAO2 | HTT 2710/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | HTT 4749/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | HTT 2323/4885 |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | TLR9, TLR7, TLR8 | HTT 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.